Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1987802
                    [Title] => Years after allhat, alpha-blocker use common, risky
                    [Summary] => The risk of cardiovascular and hypotension-related events is higher with alpha-blockers than with other hypertension drugs, but almost 20 years after the pivotal ALLHAT trial first raised safety concerns, they are still widely used, according to investigators.
                    [DatePublished] => 2020-01-26 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 1
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

        )

)

alpha-blockers

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1987802
                    [Title] => Years after allhat, alpha-blocker use common, risky
                    [Summary] => The risk of cardiovascular and hypotension-related events is higher with alpha-blockers than with other hypertension drugs, but almost 20 years after the pivotal ALLHAT trial first raised safety concerns, they are still widely used, according to investigators.
                    [DatePublished] => 2020-01-26 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 1
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

        )

)

abtest

Years after allhat, alpha-blocker use common, risky

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | January 26, 2020 - 12:00am

The risk of cardiovascular and hypotension-related events is higher with alpha-blockers than with other hypertension drugs, but almost 20 years after the pivotal ALLHAT trial first raised safety concerns, they are...

Opinion